A Swiss drug discovery startup pairing generative AI with physics-based molecular simulation to design and optimize small-molecule therapeutics.
InVirtuoLabs / Max Planck Institute of Biochemistry
Released September 30, 2025
Discrete flow generative model over fragmented SMILES for de novo, fragment-constrained, and property-optimized small-molecule drug design.